<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37545721</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-2295</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in neurology</Title><ISOAbbreviation>Front Neurol</ISOAbbreviation></Journal><ArticleTitle>Neurological manifestations of post-acute sequelae of COVID-19: which liquid biomarker should we use?</ArticleTitle><Pagination><StartPage>1233192</StartPage><MedlinePgn>1233192</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1233192</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fneur.2023.1233192</ELocationID><Abstract><AbstractText>Long COVID syndrome, also known as post-acute sequelae of COVID-19 (PASC), is characterized by persistent symptoms lasting 3-12&#x2009;weeks post SARS-CoV-2 infection. Patients suffering from PASC can display a myriad of symptoms that greatly diminish quality of life, the most frequent being neuropsychiatric. Thus, there is an eminent need to diagnose and treat PASC related neuropsychiatric manifestation (neuro-PASC). Evidence suggests that liquid biomarkers could potentially be used in the diagnosis and monitoring of patients. Undoubtedly, such biomarkers would greatly benefit clinicians in the management of patients; however, it remains unclear if these can be reliably used in this context. In this mini review, we highlight promising liquid (blood and cerebrospinal fluid) biomarkers, namely, neuronal injury biomarkers NfL, GFAP, and tau proteins as well as neuroinflammatory biomarkers IL-6, IL-10, TNF-&#x3b1;, and CPR associated with neuro-PASC and discuss their limitations in clinical applicability.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Comeau, Martin, Robichaud and Chamard-Witkowski.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Comeau</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Dr. Georges-L. Dumont University Hospital Centre, Clinical Research Sector, Vitalit&#xe9; Health Network, Moncton, NB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Mykella</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre de Formation m&#xe9;dicale du Nouveau-Brunswick, Universit&#xe9; de Sherbrooke, Moncton, NB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robichaud</LastName><ForeName>Gilles A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Biochemistry, Universit&#xe9; de Moncton, Moncton, NB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The New Brunswick Center for Precision Medicine, Moncton, NB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Atlantic Cancer Research Institute, Moncton, NB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chamard-Witkowski</LastName><ForeName>Ludivine</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Centre de Formation m&#xe9;dicale du Nouveau-Brunswick, Universit&#xe9; de Sherbrooke, Moncton, NB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Dr. Georges-L. Dumont University Hospital Centre, Moncton, NB, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Neurol</MedlineTA><NlmUniqueID>101546899</NlmUniqueID><ISSNLinking>1664-2295</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CPR</Keyword><Keyword MajorTopicYN="N">GFAP</Keyword><Keyword MajorTopicYN="N">IL-10</Keyword><Keyword MajorTopicYN="N">IL-6</Keyword><Keyword MajorTopicYN="N">NfL</Keyword><Keyword MajorTopicYN="N">TNF-&#x3b1;</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">neuro-PASC</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>7</Day><Hour>4</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>7</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37545721</ArticleId><ArticleId IdType="pmc">PMC10400889</ArticleId><ArticleId IdType="doi">10.3389/fneur.2023.1233192</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236&#x2009;379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. (2021) 8:416&#x2013;27. doi: 10.1016/S2215-0366(21)00084-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(21)00084-5</ArticleId><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. . Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. (2020) 77:683&#x2013;90. doi: 10.1001/jamaneurol.2020.1127, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.1127</ArticleId><ArticleId IdType="pmc">PMC7149362</ArticleId><ArticleId IdType="pubmed">32275288</ArticleId></ArticleIdList></Reference><Reference><Citation>Boldrini M, Canoll PD, Klein RS. How COVID-19 affects the brain. JAMA Psychiat. (2021) 78:682&#x2013;3. doi: 10.1001/jamapsychiatry.2021.0500, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2021.0500</ArticleId><ArticleId IdType="pmc">PMC9894299</ArticleId><ArticleId IdType="pubmed">33769431</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilotto A, Cristillo V, Cotti Piccinelli S, Zoppi N, Bonzi G, Sattin D, et al. . Long-term neurological manifestations of COVID-19: prevalence and predictive factors. Neurol Sci. (2021) 42:4903&#x2013;7. doi: 10.1007/s10072-021-05586-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-021-05586-4</ArticleId><ArticleId IdType="pmc">PMC8439956</ArticleId><ArticleId IdType="pubmed">34523082</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, et al. . Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. (2021) 38:101019. doi: 10.1016/j.eclinm.2021.101019, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Badenoch JB, Rengasamy ER, Watson C, Jansen K, Chakraborty S, Sundaram RD, et al. . Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis. Brain Commun. (2022) 4:fcab297. doi: 10.1093/braincomms/fcab297, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab297</ArticleId><ArticleId IdType="pmc">PMC8833580</ArticleId><ArticleId IdType="pubmed">35169700</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T, Knight M, A&#x2019;Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. (2020) 370:m3026. doi: 10.1136/bmj.m3026</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3026</ArticleId><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F, Ling S, Lui LMW, Lee Y, Gill H, Teopiz KM, et al. . Fatigue and cognitive impairment in post-COVID-19 syndrome: a systematic review and meta-analysis. Brain Behav Immun. (2022) 101:93&#x2013;135. doi: 10.1016/j.bbi.2021.12.020, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.12.020</ArticleId><ArticleId IdType="pmc">PMC8715665</ArticleId><ArticleId IdType="pubmed">34973396</ArticleId></ArticleIdList></Reference><Reference><Citation>Miskowiak KW, Fugledalen L, Jespersen AE, Sattler SM, Podlekareva D, Rungby J, et al. . Trajectory of cognitive impairments over 1 year after COVID-19 hospitalisation: pattern, severity, and functional implications. Eur Neuropsychopharmacol. (2022) 59:82&#x2013;92. doi: 10.1016/j.euroneuro.2022.04.004, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2022.04.004</ArticleId><ArticleId IdType="pmc">PMC9008126</ArticleId><ArticleId IdType="pubmed">35561540</ArticleId></ArticleIdList></Reference><Reference><Citation>Lle&#xf3; A. Biomarkers in neurological disorders: a fast-growing market. Brain Commun. (2021) 3:fcab086. doi: 10.1093/braincomms/fcab086, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab086</ArticleId><ArticleId IdType="pmc">PMC8096602</ArticleId><ArticleId IdType="pubmed">33977270</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. (2021) 27:954&#x2013;63. doi: 10.1038/s41591-021-01382-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01382-x</ArticleId><ArticleId IdType="pubmed">34083813</ArticleId></ArticleIdList></Reference><Reference><Citation>Balogun WG, Zetterberg H, Blennow K, Karikari TK. Plasma biomarkers for neurodegenerative disorders: ready for prime time? Curr Opin Psychiatry. (2023) 36:112&#x2013;8. doi: 10.1097/YCO.0000000000000851, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/YCO.0000000000000851</ArticleId><ArticleId IdType="pmc">PMC9872855</ArticleId><ArticleId IdType="pubmed">36607770</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon PJ, Panczykowski DM, Yue JK, Puccio AM, Inoue T, Sorani MD, et al. . Measurement of the glial fibrillary acidic protein and its breakdown products GFAP-BDP biomarker for the detection of traumatic brain injury compared to computed tomography and magnetic resonance imaging. J Neurotrauma. (2015) 32:527&#x2013;33. doi: 10.1089/neu.2014.3635, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2014.3635</ArticleId><ArticleId IdType="pmc">PMC4394160</ArticleId><ArticleId IdType="pubmed">25264814</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H, Blennow K. Fluid biomarkers for mild traumatic brain injury and related conditions. Nat Rev Neurol. (2016) 12:563&#x2013;74. doi: 10.1038/nrneurol.2016.127, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2016.127</ArticleId><ArticleId IdType="pubmed">27632903</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton NJ, Janelidze S, al Khleifat A, Leuzy A, van der Ende EL, Karikari TK, et al. . A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun. (2021) 12:3400. doi: 10.1038/s41467-021-23620-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23620-z</ArticleId><ArticleId IdType="pmc">PMC8185001</ArticleId><ArticleId IdType="pubmed">34099648</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton NJ, Hye A, Rajkumar AP, Leuzy A, Snowden S, Su&#xe1;rez-Calvet M, et al. . An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nat Rev Neurol. (2020) 16:265&#x2013;84. doi: 10.1038/s41582-020-0348-0, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-0348-0</ArticleId><ArticleId IdType="pubmed">32322100</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. . Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. (2018) 14:577&#x2013;89. doi: 10.1038/s41582-018-0058-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0058-z</ArticleId><ArticleId IdType="pubmed">30171200</ArticleId></ArticleIdList></Reference><Reference><Citation>Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, et al. . Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nat Med. (2019) 25:277&#x2013;83. doi: 10.1038/s41591-018-0304-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0304-3</ArticleId><ArticleId IdType="pmc">PMC6367005</ArticleId><ArticleId IdType="pubmed">30664784</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Su&#xe1;rez-Calvet M, Suridjan I, Minguill&#xf3;n C, Gispert JD, Jonaitis E, et al. . Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit. Alzheimers Res Ther. (2023) 15:25. doi: 10.1186/s13195-023-01168-y, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-023-01168-y</ArticleId><ArticleId IdType="pmc">PMC9883877</ArticleId><ArticleId IdType="pubmed">36709293</ArticleId></ArticleIdList></Reference><Reference><Citation>Delcoigne B, Manouchehrinia A, Barro C, Benkert P, Michalak Z, Kappos L, et al. . Blood neurofilament light levels segregate treatment effects in multiple sclerosis. Neurology. (2020) 94:e1201&#x2013;12. doi: 10.1212/WNL.0000000000009097, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009097</ArticleId><ArticleId IdType="pmc">PMC7387108</ArticleId><ArticleId IdType="pubmed">32047070</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson B, Alberg L, Cullen NC, Michael E, Wahlgren L, Kroksmark AK, et al. . NFL is a marker of treatment response in children with SMA treated with nusinersen. J Neurol. (2019) 266:2129&#x2013;36. doi: 10.1007/s00415-019-09389-8, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09389-8</ArticleId><ArticleId IdType="pmc">PMC6687695</ArticleId><ArticleId IdType="pubmed">31123861</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee P, Pedrini S, Stoops E, Goozee K, Villemagne VL, Asih PR, et al. . Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease. Transl Psychiatry. (2021) 11:27. doi: 10.1038/s41398-020-01137-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-020-01137-1</ArticleId><ArticleId IdType="pmc">PMC7801513</ArticleId><ArticleId IdType="pubmed">33431793</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari-Souza JP, Ferreira PCL, Bellaver B, Tissot C, Wang YT, Leffa DT, et al. . Astrocyte biomarker signatures of amyloid-&#x3b2; and tau pathologies in Alzheimer's disease. Mol Psychiatry. (2022) 27:4781&#x2013;9. doi: 10.1038/s41380-022-01716-2, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-022-01716-2</ArticleId><ArticleId IdType="pmc">PMC9734046</ArticleId><ArticleId IdType="pubmed">35948658</ArticleId></ArticleIdList></Reference><Reference><Citation>Benussi A, Ashton NJ, Karikari TK, Gazzina S, Premi E, Benussi L, et al. . Serum glial fibrillary acidic protein (GFAP) is a marker of disease severity in frontotemporal lobar degeneration. J Alzheimers Dis. (2020) 77:1129&#x2013;41. doi: 10.3233/JAD-200608, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-200608</ArticleId><ArticleId IdType="pubmed">32804092</ArticleId></ArticleIdList></Reference><Reference><Citation>Katisko K, Cajanus A, Huber N, J&#xe4;&#xe4;skel&#xe4;inen O, Kokkola T, K&#xe4;rkk&#xe4;inen V, et al. . GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performance. J Neurol Neurosurg Psychiatry. (2021) 92:1305&#x2013;12. doi: 10.1136/jnnp-2021-326487, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2021-326487</ArticleId><ArticleId IdType="pubmed">34187866</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelhak A, Huss A, Kassubek J, Tumani H, Otto M. Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci Rep. (2018) 8:14798. doi: 10.1038/s41598-018-33158-8, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-33158-8</ArticleId><ArticleId IdType="pmc">PMC6172254</ArticleId><ArticleId IdType="pubmed">30287870</ArticleId></ArticleIdList></Reference><Reference><Citation>Barro C, Healy BC, Liu Y, Saxena S, Paul A, Polgar-Turcsanyi M, et al. . Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. (2023) 10:e200052. doi: 10.1212/NXI.0000000000200052, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000200052</ArticleId><ArticleId IdType="pmc">PMC9749933</ArticleId><ArticleId IdType="pubmed">36376097</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia MA, Barreras PV, Lewis A, Pinilla G, Sokoll LJ, Kickler T, et al. . Cerebrospinal fluid in COVID-19 neurological complications: Neuroaxonal damage, anti-SARS-Cov2 antibodies but no evidence of cytokine storm. J Neurol Sci. (2021) 427:117517. doi: 10.1016/j.jns.2021.117517, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2021.117517</ArticleId><ArticleId IdType="pmc">PMC8166041</ArticleId><ArticleId IdType="pubmed">34090021</ArticleId></ArticleIdList></Reference><Reference><Citation>Ameres M, Brandstetter S, Toncheva AA, Kabesch M, Leppert D, Kuhle J, et al. . Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19. J Neurol. (2020) 267:3476. doi: 10.1007/s00415-020-10050-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10050-y</ArticleId><ArticleId IdType="pmc">PMC7345451</ArticleId><ArticleId IdType="pubmed">32647900</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter R, Hert L, de Marchis GM, Twerenbold R, Kappos L, Naegelin Y, et al. . Serum Neurofilament light chain levels in the intensive care unit: comparison between severely ill patients with and without coronavirus disease 2019. Ann Neurol. (2021) 89:610&#x2013;6. doi: 10.1002/ana.26004, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26004</ArticleId><ArticleId IdType="pubmed">33377539</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper J, Stukas S, Hoiland RL, Fergusson NA, Thiara S, Foster D, et al. . Quantification of neurological blood-based biomarkers in critically ill patients with coronavirus disease 2019. Crit Care Explor. (2020) 2:e0238. doi: 10.1097/CCE.0000000000000238, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCE.0000000000000238</ArticleId><ArticleId IdType="pmc">PMC7535554</ArticleId><ArticleId IdType="pubmed">33063038</ArticleId></ArticleIdList></Reference><Reference><Citation>Aamodt AH, H&#xf8;gest&#xf8;l EA, Popperud TH, Holter JC, Dyrhol-Riise AM, Tonby K, et al. . Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19. J Neurol. (2021) 268:3574&#x2013;83. doi: 10.1007/s00415-021-10517-6, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10517-6</ArticleId><ArticleId IdType="pmc">PMC7980743</ArticleId><ArticleId IdType="pubmed">33743046</ArticleId></ArticleIdList></Reference><Reference><Citation>De Lorenzo R, Lor&#xe9; NI, Finardi A, Mandelli A, Cirillo DM, Tresoldi C, et al. . Blood neurofilament light chain and total tau levels at admission predict death in COVID-19 patients. J Neurol. (2021) 268:4436&#x2013;42. doi: 10.1007/s00415-021-10595-6, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10595-6</ArticleId><ArticleId IdType="pmc">PMC8108733</ArticleId><ArticleId IdType="pubmed">33973106</ArticleId></ArticleIdList></Reference><Reference><Citation>Frithiof R, Rostami E, Kumlien E, Virhammar J, F&#xe4;llmar D, Hultstr&#xf6;m M, et al. . Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: a prospective study. Clin Neurophysiol. (2021) 132:1733&#x2013;40. doi: 10.1016/j.clinph.2021.03.016, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2021.03.016</ArticleId><ArticleId IdType="pmc">PMC8012169</ArticleId><ArticleId IdType="pubmed">33875374</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M, Erben Y, Marquez CP, Jansen-West KR, Franco-Mesa C, Heckman MG, et al. . Serum neurofilament light protein correlates with unfavorable clinical outcomes in hospitalized patients with COVID-19. Sci Transl Med. (2021) 13:abi7643. doi: 10.1126/scitranslmed.abi7643, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abi7643</ArticleId><ArticleId IdType="pmc">PMC8432951</ArticleId><ArticleId IdType="pubmed">34131052</ArticleId></ArticleIdList></Reference><Reference><Citation>Frontera JA, Boutajangout A, Masurkar AV, Betensky RA, Ge Y, Vedvyas A, et al. . Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia. Alzheimers Dement. (2022) 18:899&#x2013;910. doi: 10.1002/alz.12556, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12556</ArticleId><ArticleId IdType="pmc">PMC9011610</ArticleId><ArticleId IdType="pubmed">35023610</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaumont H, Kaczorowski F, San-Galli A, Michel PP, Tressi&#xe8;res B, Roze E, et al. . Cerebrospinal fluid biomarkers in SARS-CoV-2 patients with acute neurological syndromes. Rev Neurol (Paris). (2023) 179:208&#x2013;17. doi: 10.1016/j.neurol.2022.11.002, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2022.11.002</ArticleId><ArticleId IdType="pmc">PMC9708608</ArticleId><ArticleId IdType="pubmed">36610823</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin BE, Celikbilek A, Kocak Y, Saltoglu GT, Konar NM, Hizmali L. Plasma biomarkers of brain injury in COVID-19 patients with neurological symptoms. J Neurol Sci. (2022) 439:120324. doi: 10.1016/j.jns.2022.120324, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2022.120324</ArticleId><ArticleId IdType="pmc">PMC9212259</ArticleId><ArticleId IdType="pubmed">35752131</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanberg N, Ashton NJ, Andersson LM, Yilmaz A, Lindh M, Nilsson S, et al. . Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. Neurology. (2020) 95:e1754&#x2013;9. doi: 10.1212/WNL.0000000000010111, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010111</ArticleId><ArticleId IdType="pubmed">32546655</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanberg N, Simr&#xe9;n J, Ed&#xe9;n A, Andersson LM, Nilsson S, Ashton NJ, et al. . Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. EBioMedicine. (2021) 70:103512. doi: 10.1016/j.ebiom.2021.103512, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103512</ArticleId><ArticleId IdType="pmc">PMC8320425</ArticleId><ArticleId IdType="pubmed">34333238</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson BA, Visvabharathy L, Ali ST, Kang AK, Patel TR, Clark JR, et al. . Plasma biomarkers of Neuropathogenesis in hospitalized patients with COVID-19 and those with Postacute sequelae of SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm. (2022) 9:e1151. doi: 10.1212/NXI.0000000000001151, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000001151</ArticleId><ArticleId IdType="pmc">PMC8901169</ArticleId><ArticleId IdType="pubmed">35256481</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, Milone I, Bulgarelli I, Peverelli S, Colombrita C, Maranzano A, et al. . Serum neurofilament light chain levels in Covid-19 patients without major neurological manifestations. J Neurol. (2022) 269:5691&#x2013;701. doi: 10.1007/s00415-022-11233-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-022-11233-5</ArticleId><ArticleId IdType="pmc">PMC9252542</ArticleId><ArticleId IdType="pubmed">35781535</ArticleId></ArticleIdList></Reference><Reference><Citation>Esp&#xed;ndola OM, Brand&#xe3;o CO, Gomes YCP, Siqueira M, Soares CN, Lima MASD, et al. . Cerebrospinal fluid findings in neurological diseases associated with COVID-19 and insights into mechanisms of disease development. Int J Infect Dis. (2021) 102:155&#x2013;62. doi: 10.1016/j.ijid.2020.10.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.10.044</ArticleId><ArticleId IdType="pmc">PMC7591319</ArticleId><ArticleId IdType="pubmed">33127503</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariotto S, Savoldi A, Donadello K, Zanzoni S, Bozzetti S, Carta S, et al. . Nervous system: subclinical target of SARS-CoV-2 infection. J Neurol Neurosurg Psychiatry. (2020) 91:1010&#x2013;2. doi: 10.1136/jnnp-2020-323881, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-323881</ArticleId><ArticleId IdType="pmc">PMC7476308</ArticleId><ArticleId IdType="pubmed">32576611</ArticleId></ArticleIdList></Reference><Reference><Citation>Virhammar J, N&#xe4;&#xe4;s A, F&#xe4;llmar D, Cunningham JL, Klang A, Ashton NJ, et al. . Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity. Eur J Neurol. (2021) 28:3324&#x2013;31. doi: 10.1111/ene.14703, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14703</ArticleId><ArticleId IdType="pmc">PMC8518988</ArticleId><ArticleId IdType="pubmed">33369818</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Sans HM, Forman CA, Nylander AN, Ho HE, Lu S, et al. . Plasma markers of neurologic injury and inflammation in people with self-reported neurologic Postacute sequelae of SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm. (2022) 9:e200003. doi: 10.1212/NXI.0000000000200003, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000200003</ArticleId><ArticleId IdType="pmc">PMC9210548</ArticleId><ArticleId IdType="pubmed">35701186</ArticleId></ArticleIdList></Reference><Reference><Citation>Paterson RW, Benjamin LA, Mehta PR, Brown RL, Athauda D, Ashton NJ, et al. . Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes. Brain Commun. (2021) 3:fcab099. doi: 10.1093/braincomms/fcab099, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab099</ArticleId><ArticleId IdType="pmc">PMC8194666</ArticleId><ArticleId IdType="pubmed">34396099</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozzetti S, Ferrari S, Zanzoni S, Alberti D, Braggio M, Carta S, et al. . Neurological symptoms and axonal damage in COVID-19 survivors: are there sequelae? Immunol Res. (2021) 69:553&#x2013;7. doi: 10.1007/s12026-021-09220-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-021-09220-5</ArticleId><ArticleId IdType="pmc">PMC8346772</ArticleId><ArticleId IdType="pubmed">34363587</ArticleId></ArticleIdList></Reference><Reference><Citation>de Boni L, Odainic A, Gancarczyk N, Kaluza L, Strassburg CP, Kersting XAK, et al. . No serological evidence for neuronal damage or reactive gliosis in neuro-COVID-19 patients with long-term persistent headache. Neurol Res Pract. (2022) 4:53. doi: 10.1186/s42466-022-00217-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s42466-022-00217-5</ArticleId><ArticleId IdType="pmc">PMC9618412</ArticleId><ArticleId IdType="pubmed">36310154</ArticleId></ArticleIdList></Reference><Reference><Citation>DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer&#x2019;s disease. Mol Neurodegener. (2019) 14:32. doi: 10.1186/s13024-019-0333-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-019-0333-5</ArticleId><ArticleId IdType="pmc">PMC6679484</ArticleId><ArticleId IdType="pubmed">31375134</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and prospects for the future. J Intern Med. (2018) 284:643&#x2013;63. doi: 10.1111/joim.12816, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.12816</ArticleId><ArticleId IdType="pubmed">30051512</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. . Plasma P-tau181 in Alzheimer&#x2019;s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer&#x2019;s dementia. Nat Med. (2020) 26:379&#x2013;86. doi: 10.1038/s41591-020-0755-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0755-1</ArticleId><ArticleId IdType="pubmed">32123385</ArticleId></ArticleIdList></Reference><Reference><Citation>Lantero Rodriguez J, Karikari TK, Su&#xe1;rez-Calvet M, Troakes C, King A, Emersic A, et al. . Plasma p-tau181 accurately predicts Alzheimer&#x2019;s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol. (2020) 140:267&#x2013;78. doi: 10.1007/s00401-020-02195-x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02195-x</ArticleId><ArticleId IdType="pmc">PMC7423866</ArticleId><ArticleId IdType="pubmed">32720099</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. . Discriminative accuracy of plasma Phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. (2020) 324:772&#x2013;81. doi: 10.1001/jama.2020.12134, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12134</ArticleId><ArticleId IdType="pmc">PMC7388060</ArticleId><ArticleId IdType="pubmed">32722745</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, et al. . Diagnostic value of plasma phosphorylated tau181 in Alzheimer&#x2019;s disease and frontotemporal lobar degeneration. Nat Med. (2020) 26:387&#x2013;97. doi: 10.1038/s41591-020-0762-2, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0762-2</ArticleId><ArticleId IdType="pmc">PMC7101073</ArticleId><ArticleId IdType="pubmed">32123386</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun B, Tang N, Peluso MJ, Iyer NS, Torres L, Donatelli JL, et al. . Characterization and biomarker analyses of post-COVID-19 complications and neurological manifestations. Cells. (2021) 10:20386. doi: 10.3390/cells10020386, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10020386</ArticleId><ArticleId IdType="pmc">PMC7918597</ArticleId><ArticleId IdType="pubmed">33668514</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Lu S, Tang AF, Durstenfeld MS, Ho HE, Goldberg SA, et al. . Markers of immune activation and inflammation in individuals with Postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis. (2021) 224:1839&#x2013;48. doi: 10.1093/infdis/jiab490, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab490</ArticleId><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong SWX, Fong SW, Young BE, Chan YH, Lee B, Amrun SN, et al. . Persistent symptoms and association with inflammatory cytokine signatures in recovered coronavirus disease 2019 patients. Open forum. Infect Dis. (2021) 8:ofab156. doi: 10.1093/ofid/ofab156</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab156</ArticleId><ArticleId IdType="pmc">PMC8083585</ArticleId><ArticleId IdType="pubmed">34095336</ArticleId></ArticleIdList></Reference><Reference><Citation>Kappelmann N, Dantzer R, Khandaker GM. Interleukin-6 as potential mediator of long-term neuropsychiatric symptoms of COVID-19. Psychoneuroendocrinology. (2021) 131:105295. doi: 10.1016/j.psyneuen.2021.105295, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2021.105295</ArticleId><ArticleId IdType="pmc">PMC8172271</ArticleId><ArticleId IdType="pubmed">34119855</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang WY, Tan MS, Yu JT, Tan L. Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease. Ann Transl Med. (2015) 3:136. doi: 10.3978/j.issn.2305-5839.2015.03.49, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3978/j.issn.2305-5839.2015.03.49</ArticleId><ArticleId IdType="pmc">PMC4486922</ArticleId><ArticleId IdType="pubmed">26207229</ArticleId></ArticleIdList></Reference><Reference><Citation>Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, et al. . Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. (2020) 9:1123&#x2013;30. doi: 10.1080/22221751.2020.1770129, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1770129</ArticleId><ArticleId IdType="pmc">PMC7473317</ArticleId><ArticleId IdType="pubmed">32475230</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G, Wu C, Zhang Q, Wu F, Yu B, Lv J, et al. . C-reactive protein level may predict the risk of COVID-19 aggravation. Open forum. Infect Dis. (2020) 7:ofaa153. doi: 10.1093/ofid/ofaa153</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofaa153</ArticleId><ArticleId IdType="pmc">PMC7197542</ArticleId><ArticleId IdType="pubmed">32455147</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavillegrand JR, Garnier M, Spaeth A, Mario N, Hariri G, Pilon A, et al. . Elevated plasma IL-6 and CRP levels are associated with adverse clinical outcomes and death in critically ill SARS-CoV-2 patients: inflammatory response of SARS-CoV-2 patients. Ann Intensive Care. (2021) 11:9. doi: 10.1186/s13613-020-00798-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-020-00798-x</ArticleId><ArticleId IdType="pmc">PMC7804215</ArticleId><ArticleId IdType="pubmed">33439360</ArticleId></ArticleIdList></Reference><Reference><Citation>Esp&#xed;ndola OM, Gomes YCP, Brand&#xe3;o CO, Torres RC, Siqueira M, Soares CN, et al. . Inflammatory cytokine patterns associated with neurological diseases in coronavirus disease 2019. Ann Neurol. (2021) 89:1041&#x2013;5. doi: 10.1002/ana.26041, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26041</ArticleId><ArticleId IdType="pmc">PMC8014707</ArticleId><ArticleId IdType="pubmed">33547819</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Q, Zhu Z, Tan C, Zhou H, Hu Y, Shen G, et al. . Changes of serum IL-10, IL-1&#x3b2;, IL-6, MCP-1, TNF-&#x3b1;, IP-10 and IL-4 in COVID-19 patients. Int J Clin Pract. (2021) 75:e14462. doi: 10.1111/ijcp.14462, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.14462</ArticleId><ArticleId IdType="pmc">PMC8237069</ArticleId><ArticleId IdType="pubmed">34107113</ArticleId></ArticleIdList></Reference><Reference><Citation>Frontera JA, Sabadia S, Lalchan R, Fang T, Flusty B, Millar-Vernetti P, et al. . A prospective study of neurologic disorders in hospitalized patients with COVID-19 in new York City. Neurology. (2021) 96:e575&#x2013;86. doi: 10.1212/WNL.0000000000010979, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010979</ArticleId><ArticleId IdType="pmc">PMC7905791</ArticleId><ArticleId IdType="pubmed">33020166</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C, Huang Y, Shi F, Tan K, Ma Q, Chen Y, et al. . C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. J Med Virol. (2020) 92:856&#x2013;62. doi: 10.1002/jmv.25871, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25871</ArticleId><ArticleId IdType="pmc">PMC7262341</ArticleId><ArticleId IdType="pubmed">32281668</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonetto V, Pasetto L, Lisi I, Carbonara M, Zangari R, Ferrari E, et al. . Markers of blood-brain barrier disruption increase early and persistently in COVID-19 patients with neurological manifestations. Front Immunol. (2022) 13:1070379. doi: 10.3389/fimmu.2022.1070379, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1070379</ArticleId><ArticleId IdType="pmc">PMC9798841</ArticleId><ArticleId IdType="pubmed">36591311</ArticleId></ArticleIdList></Reference><Reference><Citation>Spudich S, Nath A. Nervous system consequences of COVID-19. Science. (2022) 375:267&#x2013;9. doi: 10.1126/science.abm2052</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm2052</ArticleId><ArticleId IdType="pubmed">35050660</ArticleId></ArticleIdList></Reference><Reference><Citation>Boldrini M, Canoll PD, Klein RS. How does COVID-19 affect the brain? Tidsskr Nor Laegeforen. (2020) 140:444. doi: 10.4045/tidsskr.20.0444</Citation><ArticleIdList><ArticleId IdType="doi">10.4045/tidsskr.20.0444</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Needham EJ, Chou SHY, Coles AJ, Menon DK. Neurological implications of COVID-19 infection. Neurocrit Care. (2020) 32:667&#x2013;71. doi: 10.1007/s12028-020-00978-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12028-020-00978-4</ArticleId><ArticleId IdType="pmc">PMC7188454</ArticleId><ArticleId IdType="pubmed">32346843</ArticleId></ArticleIdList></Reference><Reference><Citation>Frontera J, Mainali S, Fink EL, Robertson CL, Schober M, Ziai W, et al. . Global consortium study of neurological dysfunction in COVID-19 (GCS-NeuroCOVID): study design and rationale. Neurocrit Care. (2020) 33:25&#x2013;34. doi: 10.1007/s12028-020-00995-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12028-020-00995-3</ArticleId><ArticleId IdType="pmc">PMC7243953</ArticleId><ArticleId IdType="pubmed">32445105</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai YJ, Liu SH, Manachevakul S, Lee TA, Kuo CT, Bello D. Biomarkers in long COVID-19: a systematic review. Front Med (Lausanne). (2023) 10:1085988. doi: 10.3389/fmed.2023.1085988, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1085988</ArticleId><ArticleId IdType="pmc">PMC9895110</ArticleId><ArticleId IdType="pubmed">36744129</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>